These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 28631628)
1. The absence of CD56 expression can differentiate papillary thyroid carcinoma from other thyroid lesions. Golu I; Vlad MM; Dema A; Moleriu LC; Tudor A; Iacob M; Popa O; Cornianu M Indian J Pathol Microbiol; 2017; 60(2):161-166. PubMed ID: 28631628 [TBL] [Abstract][Full Text] [Related]
2. Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin. Ceyran AB; Şenol S; Şimşek BÇ; Sağıroğlu J; Aydın A Int J Clin Exp Pathol; 2015; 8(4):3670-80. PubMed ID: 26097548 [TBL] [Abstract][Full Text] [Related]
3. Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics. Abouhashem NS; Talaat SM Pathol Res Pract; 2017 May; 213(5):509-517. PubMed ID: 28214214 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of the diagnostic value of emerin and CD56 in papillary thyroid carcinoma - an immunohistochemical study. Abdou AG; Abdelwahed M; Said A; Taie DM; Fahmy S J Immunoassay Immunochem; 2018; 39(5):521-537. PubMed ID: 30188764 [TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of CD56 immunohistochemistry in thyroid lesions. Pyo JS; Kim DH; Yang J Int J Biol Markers; 2018 May; 33(2):161-167. PubMed ID: 29799356 [TBL] [Abstract][Full Text] [Related]
6. CD56 expression in benign and malignant thyroid lesions. Muthusamy S; Azhar Sha S; Abdullah Suhaimi SN; Kassim N; Mahasin M; Mohd Saleh MF; Md Isa N Malays J Pathol; 2018 Aug; 40(2):111-119. PubMed ID: 30173227 [TBL] [Abstract][Full Text] [Related]
7. [Differential protein expressions in papillary thyroid carcinoma patients with or without Hashimoto's thyroiditis]. Lu HZ; Zhang N; Liu W; Zhu XY; Qi D; Wang Y; Liu XY; Li ZJ Zhonghua Zhong Liu Za Zhi; 2020 Jun; 42(6):463-468. PubMed ID: 32575941 [No Abstract] [Full Text] [Related]
8. Diagnostic value of CD56 and nm23 markers in papillary thyroid carcinoma. Shahebrahimi K; Madani SH; Fazaeli AR; Khazaei S; Kanani M; Keshavarz A Indian J Pathol Microbiol; 2013; 56(1):2-5. PubMed ID: 23924549 [TBL] [Abstract][Full Text] [Related]
9. Expression of HBME-1 and CD56 in follicular variant of papillary carcinoma in children: An immunohistochemical study and their diagnostic utility. Skaria PE; Ahmed AA; Yin H; Nicol K; Reid KJ; Singh V Pathol Res Pract; 2019 May; 215(5):880-884. PubMed ID: 30711197 [TBL] [Abstract][Full Text] [Related]
10. Diagnostic utility of CD56 immunohistochemistry in papillary carcinoma of the thyroid. El Demellawy D; Nasr AL; Babay S; Alowami S Pathol Res Pract; 2009; 205(5):303-9. PubMed ID: 19153015 [TBL] [Abstract][Full Text] [Related]
11. Cytokeratin subtypes in thyroid tumours: immunohistochemical study with emphasis on the follicular variant of papillary carcinoma. Cameron BR; Berean KW J Otolaryngol; 2003 Oct; 32(5):319-22. PubMed ID: 14974863 [TBL] [Abstract][Full Text] [Related]
12. Follicular variant of papillary thyroid carcinoma is a unique clinical entity: a population-based study of 10,740 cases. Yu XM; Schneider DF; Leverson G; Chen H; Sippel RS Thyroid; 2013 Oct; 23(10):1263-8. PubMed ID: 23477346 [TBL] [Abstract][Full Text] [Related]
13. Potential diagnostic utility of CD56 and claudin-1 in papillary thyroid carcinoma and solitary follicular thyroid nodules. Abd El Atti RM; Shash LS J Egypt Natl Canc Inst; 2012 Dec; 24(4):175-84. PubMed ID: 23159288 [TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of HBME-1, CD56, Galectin-3 and Cytokeratin-19 in papillary thyroid carcinomas and thyroid tumors of uncertain malignant potential. Nechifor-Boilă A; Cătană R; Loghin A; Radu TG; Borda A Rom J Morphol Embryol; 2014; 55(1):49-56. PubMed ID: 24715165 [TBL] [Abstract][Full Text] [Related]
15. CD56, CD57, HBME1, CK19, Galectin-3 and p63 immunohistochemical stains in differentiating diagnosis of thyroid benign/malign lesions and NIFTP. Tastekin E; Keskin E; Can N; Canberk S; Mut A; Erdogan E; Asa N; Güldiken S; Sezer A; Azatcam M Pol J Pathol; 2019; 70(4):286-294. PubMed ID: 32146798 [TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical expression of HBME-1, E-cadherin, and CD56 in the differential diagnosis of thyroid nodules. Ozolins A; Narbuts Z; Strumfa I; Volanska G; Stepanovs K; Gardovskis J Medicina (Kaunas); 2012; 48(10):507-14. PubMed ID: 23324246 [TBL] [Abstract][Full Text] [Related]
17. Bethesda classification is a valuable guide for fine needle aspiration reports and highly predictive especially for diagnosing aggressive variants of papillary thyroid carcinoma. Evranos B; Polat SB; Baser H; Ozdemir D; Kilicarslan A; Yalcin A; Ersoy R; Cakir B Cytopathology; 2017 Aug; 28(4):259-267. PubMed ID: 27666595 [TBL] [Abstract][Full Text] [Related]
18. Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid. El Demellawy D; Nasr A; Alowami S Diagn Pathol; 2008 Feb; 3():5. PubMed ID: 18254952 [TBL] [Abstract][Full Text] [Related]
19. Differentiation of the Follicular Variant of Papillary Thyroid Carcinoma From Classic Papillary Thyroid Carcinoma: An Ultrasound Analysis and Complement to Fine-Needle Aspiration Cytology. Ng SC; Kuo SF; Hua CC; Huang BY; Chiang KC; Chu YY; Hsueh C; Lin JD J Ultrasound Med; 2018 Mar; 37(3):667-674. PubMed ID: 28880405 [TBL] [Abstract][Full Text] [Related]
20. Papillary thyroid tumors: Diagnostic value of CD56 and Cytokeratin 19. Zehani A; Bani A; Chelly I; Rejaibi S; Besbes G; Haouet S; Kchir N Tunis Med; 2018 Feb; 96(2):113-121. PubMed ID: 30324976 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]